This educational Case Escalation Series is designed to improve your use of PI3K-pathway inhibitors for eligible patients with hormone-receptor‒positive, HER2-negative metastatic breast cancer through personalized and multidisciplinary treatment planning and adverse event management, as well as improved recognition of barriers to delivery of guideline-concordant care. This activity is comprised of three interactive, video-based modules that escalate in complexity. Each module includes a brief clinical primer, followed by case presentation and discussion. Throughout the modules, you will have the opportunity to share your approaches and perspectives, while watching the expert faculty provide evidence-based rationale for their own strategies. The activity also includes point-of-care resources such as personalized posters and video micromodules.
RELEASED DATE: October 02, 2025
EXPIRATION DATE: October 22, 2026